HPV Reflex Testing in Menopausal Women by Ko, Emily M. et al.
SAGE-Hindawi Access to Research
Pathology Research International
Volume 2011, Article ID 181870, 4 pages
doi:10.4061/2011/181870
Clinical Study
HPV Reﬂex Testing in Menopausal Women
EmilyM. Ko,1 Rosemary Tambouret,2 DavidWilbur,2 andAnnekathrynGoodman1
1MGH/Vincent Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Massachusetts General Hospital,
Boston, MA 02114, USA
2Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA
Correspondence should be addressed to Annekathryn Goodman, agoodman@partners.org
Received 7 November 2010; Accepted 29 January 2011
Academic Editor: Nirag Jhala
Copyright © 2011 Emily M. Ko et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Objective. To determine the frequency of high risk (HR) HPV and intraepithelial neoplasia following ASCUS pap cytology screens
in menopausal women. Study Design. Following IRB approval, we performed a retrospective review of all cases of ASCUS pap
tests, HPV results, and relevant clinical-pathologic data in women age 50 or over from November 2005 to January 2007 within a
tertiary care center. Statistical analyses were performed in EXCEL. Results. 344 patients were analyzed for a total of 367 screening
pap tests. 25.29% (87/344) patients were HR HPV positive, with greater percentages of HR HPV cases occurring in women age 65–
74. Within HR HPV cases, 79.3% (69/87) underwent colposcopy. 27.5% (19/69) biopsy proven lesions were discovered, including
cervical, vulvar or vaginal (intraepithelial neoplasia). Within the negative HR HPV group 3.1% (8/257) patients were diagnosed
with dysplasia or carcinoma. Within both HR HPV positive and negative groups, patients with no prior history of lower genital
tract lesions or cancer were identiﬁed. Conclusion. Reﬂex HPV testing plays an important role in ASCUS triage in menopausal
women. Pap test screening and HPV testing should not be limited to women of reproductive age as they may aid in the diagnosis
of intraepithelial neoplasia in women of older age.
1.Introduction
Cervical cancer remains the fourth leading cause of cancer
mortality in women worldwide today [1]. It is estimated
that 12,200 new cases of cervical cancer will be diagnosed
in the US in 2010, with 4210 deaths due to the disease [2].
Approximately 60% of cervical cancers occur in women over
the age 45, and 20% in women over age 65 [3].
Most studies on cervical cancer screening have focused
on premenopausal women, with little information provided
on the perimenopausal or postmenopausal (PMP) popula-
tion. However, these women remain at increased risk for
cervical cancer given that there is a secondary peak in preva-
lence of high-risk HPV subtypes in this older population [4],
and that certain high-risk HPV subtypes persist to a greater
extent in this population [5]. Unfortunately, many of these
olderwomenhavenothadregularaccesstogynecologiccare,
or cervical cancer screening. Of menopausal women who
were diagnosed with invasive cervical cancer, 50% of women
over age 65 had not had a pap smear in the past three years
[6]. Approximately, one quarter of elderly women have never
been screened by pap testing [7].
Furthermore, there is very limited data available on
HPV infection and lower genital tract disease in menopausal
women. Given that high-risk (HR) HPV reﬂex testing has
increased the detection of Cervical Intraepithelial Neoplasia
(CIN) based on the US National Cancer Institute ASCUS-
LSIL Triage Study [8], we seek to determine the rate of HPV-
positive infection by reﬂex testing in menopausal women
with abnormal pap cytology of Atypical Squamous Cells of
Undetermined Signiﬁcance (ASCUS). This study also seeks
to determine the frequency of lower genital tract disease,
including CIN, vulvar intraepithelial neoplasia (VIN), and
vaginal intraepithelial neoplasia (VAIN) in this population.
2. Methods
Thissingle-institutionstudywasconductedafterapprovalby
and following guidelines set forthby the Institutional Review
Board. Pap cytology tests were obtained by obstetrician-
gynecologists, internal medicine primary care physicians, as
well as gynecologic-oncologists. Tests were done primarily at
atertiarycarecenter,withasmallpercentageofcasesreceived
from local aﬃliated community health centers.2 Pathology Research International
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Figure 1: Age distribution of all ASCUS cases.
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Figure 2: Percent of HPV+ ASCUS cases per age group.
Using a pathology database from November of 2005 to
January 2007, all cases of ASCUS in women aged 50 or over
were retrospectively identiﬁed. Starting in November 2005,
all cases of ASCUS pap results automatically underwent
reﬂex high-risk (HR) HPV testing using the Digene Hybrid
Capture II System (Qiagen, Valencia, CA, 2003). The Sure
Path (TriPath Imaging Inc, Burlington, North Carolina,
2003) system was used to process all cytology specimens.
Follow-up colposcopy and biopsy results were obtained
from the electronic medical record. These exams were
performed by both general obstetrician-gynecologists, nurse
practitioners supervised by obstetrician gynecologists, and
gynecologic-oncologists. Additionally, demographic infor-
mation including age, race, age of menopause, past medical
history, and past gynecologic history was collected.
Data was entered in Excel. Basic distribution statistics
were performed in Excel.
3. Results
344 patients were analyzed, with a total of 367 ASCUS cases.
Therewere22patientswhowerescreenedtwiceandonewho
was screened three times during this interval.
The mean age of menopause was 49.5 (SD 22.5) years.
The mean age of subjects was 59.8 (SD 8.7) years. 17.4%
(60/344) of patients were past smokers, and 11.04% (38/344)
Table 1: Biopsy proven lesions following ASCUS cytology results.
Biopsy proven Prior gynecologic diagnoses
Diagnosis
HPV positive
CIN I 7
4/7: No abnormal history
2/7: LSIL
1/7: CIN II
CIN II 2 1/2: LSIL
1/2: CIN III
CIN III 2 1/2: No abnormal history
1/2: AGUS
VAIN I 2 1/2: No abnormal history
1/2: Cervical SCC
VAIN II 1 1/1: No abnormal history
VAIN III 2
1/2: Cold knife cone
(pathology unavailable)
1/2: CIN III
VIN III + SCC 1 1/1: Vulvar SCC
HPV negative
CIN I 1 1/1: CIN 1
VAIN II 1 1/1: CIN I, VAIN I
VAIN III 1 1/1: CIN II, VAIN I
Vaginal SCC 1 1/1: No abnormal history
Vulvar CIS 1 1/1: Vulvar CIS
Vulvar SCC 1 1/1: Vulvar SCC
Endometrial
cancer 2 2/2: No abnormal history
Biopsy proven results following ASCUS cytology, and reﬂex HR HPV
testing.CIN.Cervicalintraepithelialneoplasia.VAIN.Vaginalintraepithelial
neoplasia. VIN. Vulvar intraepithelial neoplasia. CIS. Carcinoma in situ.
SCC. Squamous cell carcinoma.
currently smoke. Overall, 46.5% (160/344) are currently
married. 12.2% (42/344) are currently divorced and single,
and 10.5% (36/344) are divorced or widowed with a new
sexual partner at the time of the exam. Hypertension was
the most frequently reported medical condition, present
in 33.1% (114/344) of all cases. Conditions that may
aﬀect HPV-related diseases, such as, lupus, hepatitis, and
postorgan transplantation occurred infrequently.
In review of past gynecologic history, 42.7% (147/344)
of patients never had an abnormal pap smear. 44.8%
(154/344) of patients had been previously diagnosed with
ASCUS. 15.7% (54/344) had history of CIN, and 3.5%
(12/344) had history of cervical carcinoma in situ (CIS) and
squamous cell carcinoma (SCC). 8.4% (29/344) had history
of VIN. 14.0% (48/344) had prior hysterectomies, for either
malignant or benign indications. In total, 20.3% (70/344)
had a documented history of CIN, VIN, or VAIN.
The majority of ASCUS cases occurred in women age
50–60, in which 56% of patients were less than 60 years oldPathology Research International 3
Table 2: Cervical cancer screening guidelines in PMP women.
Organization Recommendation
American Congress of
Obstetricians and Gynecologists
(i) Inconclusive evidence to set the upper age limit at which to stop cervical cancer screening
(ii) Following hysterectomy for benign indications and with no prior history of CIN or cancer
may discontinue screening
American Cancer Society
(i) Women ageing 70+ who had 3 consecutive negative pap screens and no abnormal screens
within the past 10 years may stop screening, if they do not have a history of cancer,
diesthylstilbesterol exposure, HIV, or suppressed immune status
(ii) Following hysterectomy for benign indications and with no prior history of CIN or cancer
may discontinue screening
United States Preventative Task
Force
(i) Women of age 65+ with history of prior negative screens and who are deemed not at high
risk for cervical cancer may stop cervical cancer screening
(ii) Following hysterectomy for benign indications, cervical cancer screening can be stopped
completely
(Figure 1). With increasing age, there were fewer cases of
ASCUS.
Of these ASCUS samples, 25.3% (87/344) patients were
HR HPV positive. This included all patients who on ﬁrst
pass were HR HPV positive, as well as one patient who was
screened twice in this interval, who was ﬁrst negative for HR
HPV, and then positive. The greatest percent of HPV positive
cases by age occurred within the age group of 65–74 group
(Figure 2).
Of patients who underwent repeated screens during our
study period: 5 patients were negative on both screens (of
which1patientwasdiagnosedwithVAINI).12patientswere
positiveonbothscreens(ofwhichonepatientwasdiagnosed
with CIN I, one with CIN2, and one with vulvar SCC).
1 patient was positive on 3 screens. 3 patients were positive
onﬁrstscreen,thenconvertedtonegative(ofwhich1patient
wasdiagnosedwithVAINIII).1patientwasnegativeinitially,
and then positive on repeat screen.
Of the HPV positive patients, 79.3% (69/87) underwent
colposcopy. 27.5% (19/69) of biopsy proven lesions were
discovered, including CIN, VAIN, and VIN. Biopsy results
revealed 7 patients with CIN I, 2 patients with CIN II, 2
patients with CIN III, 5 patients with VAIN and 1 patient
with VIN. Table 1 summarizes these ﬁndings.
Of the HPV positive patients who did not initially receive
colposcopy, further analysis showed that one patient under-
went hysterectomy with no abnormal ﬁndings; 4 patients
underwent colposcopy which were all negative; 3 patients
underwent vaginal exam only (given prior hysterectomy)
which were negative. 3 patients had no followup and are
presumed to be lost to followup. The remaining patients all
had at least repeat pap exams.
Within the negative HR HPV group, 11.7% (30/257)
patients underwent colposcopy. While current guidelines do
not recommend colposcopy in HPV-negative women, in
2005, some women were still being treated based on older
recommendations for colposcopy for atypical pap smears.
Three percent of patients (8/257) were diagnosed with CIN,
VIN, VAIN, or carcinoma. Findings included: one with
CIN 1, one with VAIN II, one with VAIN III, one with
newly diagnosed vaginal SCC, one with vulvar CIS, one with
vulvar SCC, and 2 with newly diagnosed endometrial cancer.
Table 1 summarizes these ﬁndings with each individual’s
prior gynecologic history.
Overall, 7.8% of patients with ASCUS had positive col-
poscopicﬁndings(19HPV-positiveplus8HPV-negativecol-
poscopy biopsy proven cases/344). HPV triage allowed iden-
tiﬁcation of 19/27 (70.3%) of the dysplastic or cancer cases.
4. Discussion
Despite the common assumption that peri- and post-
menopausal (PMP) women are at low risk for lower genital
tract disease, we found that 25% of ASCUS patients who
were age 50 years or older had high-risk HPV. Within each
ﬁve-year age bracket starting at 50, the greatest percentage of
HRHPVoccurredwithinwomenaged60–70s.Furthermore,
several of these women with biopsy proven diagnoses of
lower genital tract disease had no prior history of HPV-
related gynecologic disease. We presume that these cases
are due to newly acquired infections. Without continued
surveillance and gynecologic care, many PMP women may
suﬀer from undiagnosed lower genital tract disease.
Furthermore, 27% of HR HPV-positive patients were
found to have a biopsy proven abnormality, including CIN,
VIN, VAIN, or cancer. Even in the HPV-negative group,
3% of patients had biopsy proven disease, including two
who have never had lower genital tract disease. They were
newly diagnosed with endometrial cancer. Since we could
not accurately diﬀerentiate women with a remote history
of lower genital tract disease from those with more recent
abnormalities, we did not exclude patients undergoing
follow-up surveillance for recent abnormalities. Therefore,
we reported all ﬁndings seen at this tertiary care center.
Although these rates of lower genital tract abnormalities may
be higher than that of the general PMP population, use of
the pap cytology screening and HPV reﬂex testing helped
identifyalargeproportionofPMPwomenwithlowergenital
tract disease.
Our results are consistent with other reports regarding
the presence of lower genital tract disease, including HPV-
related disease in PMP women. In a recent study of HR HPV4 Pathology Research International
AS C U So u t c o m e si nP M Pw o m e na g e4 5y e a r sa n do l d e r ,
25.4% of ASCUS samples were HR HPV positive, similar to
ours. Of these women, 30.9% revealed persistent LSIL/CIN1
and 3.68% were diagnosed with HSIL/CIN2or 3, with one
patient diagnosed with squamous cell carcinoma (0.74%)
[9]. Furthermore, in a recent study published from the
Netherlands, the incidence of cervical cancer 10 years after
havinghadthreeconsecutivenegativepapsmearswassimilar
for older women aged 45–55 (41/100,000, with 95% CI 33–
51) versus younger women, aged 30–44 years (36/100,000
with 95% CI 24–52), P = .48 [10]. Contrary to common
belief that the incidence of cervical cancer would decrease
with increased age, the incidence of cancer remained nearly
the same, in this large national cohort of women. Even after
three negative pap tests, PMP women may warrant further
surveillance.
Although guidelines for cervical cancer screening remain
quite variable, our ﬁndings suggest that a signiﬁcant pro-
portion of PMP have new or persistent lower genital tract
disease. Screening recommendations by various health orga-
nizations have been summarized in Table 2. Considerations
for continued gynecologic examinations, pap cytology exam,
and reﬂex HPV testing are important tools for identiﬁcation
and treatment of PMP women. In a rapidly growing elderly
and PMP population, relatively little information is available
regarding thefrequencyand occurrenceof lower genital tract
disease. The acquisition and persistence of HPV-related dis-
ease may diﬀer in this population due to physiologic changes
of menopause. Several PMP women had persistence of HR
HPV while others cleared the infection on repeat exams in
our study. Given the extent of lower genital tract disease
found in our population compared to the relatively limited
information reported about PMP women, we propose that
the epidemiologic and social-behavioral patterns of PMP
women may be underrecognized and underreported, both in
regards to sexually transmitted infections and non-sexually
transmitted diseases of the lower genital tract.
The strengths of this study include that it was a single-
institution study, with a designated gynecologic pathology
department, diagnosing both cytologic as well as histo-
logic specimens. The samples were aggregated from both
community clinics aﬃliated with the institution as well as
gynecologic-oncology subspecialty departments. The use of
reﬂex testing was standardized during this time interval.
Limitations of the study include the relatively small
number of cases. Given that the occurrence of HPV-related
genital disease is relatively uncommon, the frequencies
reported in this study could be falsely elevated due to the
referralbase to a gynecologic oncology department, specialty
colposcopy clinic, and gynecologic-pathology department
within a large tertiary care center. Secondly, the actual
incidence of HR HPV in this population is unknown. To our
knowledge, the rate of lower genital tract disease in this older
population remains undeﬁned.
In summary, PMP women remain susceptible to HPV
related lower genital tract disease. Reﬂex HPV testing
identiﬁed a signiﬁcant fraction of patients with lower genital
tract disease. Despite their increased age, these women
should not be disregarded and should continue to undergo
routine gynecologic exams, pap cytology testing, and reﬂex
HPV testing in the appropriate clinical context. Reﬂex HPV
remains a useful modality for identifying several treatable
lower genital tract diseases in this older population.
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